10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Performance - 10x Genomics announced preliminary Q4 and full year 2025 results, reporting approximately $599 million in revenue for the full year and $166 million in Q4, exceeding the high end of their Q4 guidance [2] - The company generated about $40 million in cash, bringing its balance sheet to over $0.5 billion [2] Management Commentary - The CEO expressed pride in the team's performance amidst significant upheavals in various end markets, highlighting strong execution throughout the year [3] - The company experienced positive momentum in key metrics driving business fundamentals, multiple new product launches, and a strengthened balance sheet, positioning the company in its strongest state ever [3]